Crossmark

Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRASG12C inhibitor-naïve Chinese patients with KRASG12C-mutated metastatic colorectal cancer: a pooled analysis from phase I part of two studies

Crossref DOI link: https://doi.org/10.1038/s41392-025-02315-7

Published Online: 2025-07-25

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yuan, Ying https://orcid.org/0000-0002-3922-9553
Deng, Yanhong

Jin, Yongdong

Guo, Zengqing

Pan, Yueyin

Wang, Cunji

Wang, Zhiwu

Hu, Yi

Hua, Dong

Meng, Xiangjiao

Zhang, Zhiye

Zhao, Mingfang

Dong, Xiaorong

Huang, Dingzhi

Li, Xiaoyan

Liu, Lian

Sun, Meili

Wang, Huijuan

Wang, Xiuwen

Yang, Nong

Zhang, Mingjun

Hu, Sheng

Wu, Dongde

Huang, Jingjing

Zhang, Sujie

Huang, Mengna

Ding, Kefeng
License Information

Text and Data Mining valid from 2025-07-25

Version of Record valid from 2025-07-25
More Information

Article History

Received: 14 November 2024

Revised: 11 June 2025

Accepted: 24 June 2025

First Online: 25 July 2025

Competing interests

: J.H., S.Z., and M.H. are employees of Innovent Biologics. The remaining authors have no competing interests to declare.

Document is current

Any future updates will be listed below